Neuroscience: Exploratory Clinical Trials of Investigational Agents

Deadline
Multiple
OPPORTUNITY NO.
PAR-16-155
MECHANISM
U01
RESEARCH AREA(S)
SYNOPSIS

NeuroNEXT Clinical Trials

This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies.  Diseases chosen for study should be based on the NINDS’ strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). 

Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure.  The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study.  The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support.  The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.

Applicants do not need to be part of the existing NeuroNEXT infrastructure.   

Deadlines:

• Pre-Application Submission: N/A
• Application Submission: 5:00 PM local time of applicant organization, Apr. 4, 2017; Aug. 3, 2017

Companion funding opportunities:

ELIGIBILITY

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.